Cardiovascular safety of vibegron, a new β3‐adrenoceptor agonist, in older patients with overactive bladder: Post‐hoc analysis of a randomized, placebo‐controlled, double‐blind comparative phase 3 study

AIMS: To examine the safety and efficacy of vibegron, a new β3‐adrenoceptor agonist, in patients aged ≥65 years, with a focus on the effects on cardiovascular system and overactive bladder (OAB) symptoms. METHODS: A post‐hoc subgroup analysis was performed of a randomized, placebo‐controlled, double...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Masaki, Takeda, Masayuki, Gotoh, Momokazu, Yokoyama, Osamu, Kakizaki, Hidehiro, Takahashi, Satoru, Masumori, Naoya, Nagai, Shinji, Minemura, Kazuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Clinical Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362047/
https://www.ncbi.nlm.nih.gov/pubmed/34139038
http://dx.doi.org/10.1002/nau.24732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362047/
https://www.ncbi.nlm.nih.gov/pubmed/34139038
http://dx.doi.org/10.1002/nau.24732

Ejemplares similares